Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > ZGEN > Summary

ZymoGenetics, Inc.
(ZGEN)

5.05USD   Down 0.07 (1.37%)   
At 2:30AM IST
 ZymoGenetics, Inc. (NGM:ZGEN) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 5.05USD
Trade Time:2:30AM IST
Change:Down 0.07 (1.37%) 
Prev Close:5.12
Open:5.21
Bid:N/A
Ask:6.20 x 300
1y Target Est:6.88
Day's Range:5.02 - 5.28
52wk Range:3.12 - 7.31
Volume:174,740
Avg Vol (3m):431,422
Market Cap:349.87M
P/E (ttm):N/A
EPS (ttm):-0.95
Div & Yield:N/A (N/A%)
Add ZGEN to Portfolio   Download Data

HEADLINES

 
•ZymoGenetics to Host Conference Call and Webcast on February 11, 2010 to Discuss 2009 Year-end Financial Results - Business Wire  - Thu, Feb 4
•New Publication Supports Safety Profile of RECOTHROM® Thrombin, Topical (Recombinant) in Numerous Surgical Settings - Business Wire  - Tue, Feb 2
•ZYMOGENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - EDGAR Online  - Tue, Jan 12
•ZymoGenetics Announces Full Exercise of Overallotment Option by Underwriters - Business Wire  - Tue, Jan 12
•Novo Nordisk buys ZymoGenetics shares - bizjournals.com  - Tue, Jan 12
•Idenix Pharma shares rise on hepatitis study data - AP  - Mon, Jan 11
•ZYMOGENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial - EDGAR Online  - Fri, Jan 8
•ZymoGenetics Raising Money - Zacks.com  - Thu, Jan 7
•ZymoGenetics offering $79 million in common stock - AP  - Thu, Jan 7
•ZymoGenetics Prices Public Offering of Common Stock - Business Wire  - Thu, Jan 7
•Pacific Ethanol, ZymoGenetics: Early Volume Plays - TheStreet.com  - Thu, Jan 7
» More Headlines for ZGEN...

ANALYST

 
EPS Est (next year) (Dec-09) :-0.63
EPS Est (in 2 years) (Dec-10) :-0.80
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, can...

» Full Company Profile